Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

Business Leaders

Aktuelle NewsUnternehmenMärkteWirtschaft & ForexRohstoffeZinssätzeBusiness LeadersInstitutionelle AnlegerTermineSektoren 
HomeAlle NewsMeistgelesene ArtikelBusiness Leaders Biografien
Übersicht 
Founder of 7 different companies, including: Edgewise Therapeutics, Inc., Silverback Therapeutics, Inc. and Corvus Pharmaceuticals, Inc. Peter A. Thompson is an American entrepreneur and businessperson who has been at the helm of 7 different companies and occupies the position of Chairman at Silverback Therapeutics, Inc. (which he founded in 2016), Chairman for Edgewise Therapeutics, Inc. (which he founded in 2017), chairman of Principia Biopharma, Inc. and General Partner of OrbiMed Advisors Private Equity. Peter A. Thompson is also Professor at the University of Washington and on the board of 10 other companies.

In his past career Dr. Thompson held the position of Director at Response Biomedical Corp., Vice President-Research & Technology at BD Biosciences, Systems & Reagents, Inc., Venture Partner at ATP Capital LP, Managing Director at Strategicon Partners (he founded the company in 2011), Chairman, President & Chief Executive Officer of Emergent Product Development Seattle (he founded the company in 1999), Chairman at Principia Biopharma, Inc., Chairman & Chief Executive Officer of Newyu, Inc. (he founded the company), Vice President-Research & Technology Development at Becton Dickinson Immunocytometry Systems and Vice President & General Manager-Informatics at Chiron Corp.

He received an undergraduate degree from Brown University and a doctorate from The Warren Alpert Medical School.


Aktuelle Stellungen und Verantwortungsbereiche Peter A. Thompson 
NameTitel Seit
Principia Biopharma Inc.
(Biotechnologie)
chairman 2013
Edgewise Therapeutics, Inc.
(Biotechnologie)
Chairman 2017
Janux Therapeutics, Inc.
(Biotechnologie)
Independent Director 2021
Alpine Immune Sciences, Inc.
(Biotechnologie)
Independent Director 2016
Silverback Therapeutics, Inc.
(Biotechnologie)
Chairman 2016
Decibel Therapeutics, Inc.
(Biotechnologie)
Director 2020
Corvus Pharmaceuticals, Inc.
(Biotechnologie)
Independent Director 2014
Cardioxyl Pharmaceuticals, Inc. Director -
Cleave Therapeutics, Inc. Director 2010
OxOnc Development LP Director -
ReCode Therapeutics, Inc. Director -
E-Scape Bio, Inc. Director -
Angel Pharmaceuticals Co., Ltd. Director -
University of Washington Professor 2010
OrbiMed Advisors Private Equity General Partner -


Anteile an Peter A. Thompson 
NameAktien%Wert
Silverback Therapeutics, Inc. (SBTX)
(Biotechnologie)
00,0000%0 USD
Janux Therapeutics, Inc. (JANX)
(Biotechnologie)
00,0000%0 USD
Alpine Immune Sciences, Inc. (ALPN)
(Biotechnologie)
00,0000%0 USD
Corvus Pharmaceuticals, Inc. (CRVS)
(Biotechnologie)
00,0000%0 USD
Decibel Therapeutics, Inc. (DBTX)
(Biotechnologie)
00,0000%0 USD


Peter A. Thompson: Persönliches Netzwerk 
Meistgelesene News 
11.01.JAMIE DIMON : JPMorgan's Dimon sagt, dass es 6-9 Monate dauern kann, bis sich das Wachstum der Verbraucherkredite wieder normalisiert
MR
14.01.ELON MUSK : Tesla-Waren können mit Dogecoin gekauft werden, sagt Musk in einem Tweet
MR
14.01.JACK DORSEY : Jack Dorseys Block will ein offenes Bitcoin-Schürfsystem aufbauen
MR
10.01.BRUNELLO CUCINELLI : Luxuskonzern Cucinelli verzeichnet 31% Umsatzplus im Jahr 2021
MR
07.01.CHRISTIAN KLEIN : Deutschlands Vorzeige-Tech-Konzern am Scheideweg
DP
07.01.TIM COOK : Apple-Chef Cook erhält für 2020 fast 100 Millionen Dollar
RE
12.01.MARTIN SORRELL : Sorrells S4 übertrifft die Prognosen bei weitem
MR
10.01.PAUL SCHULER : Jahresumsatz von 9,15 Milliarden Franken erwartet
AW
10.01.Estelle Brachlianoff wird nächste CEO von Veolia
MR
12.01.GORDON RISKE : Mit neuem Chef ins neue Jahr
DP
Weitere Nachrichten und Newsletter


© 2022 People and Ownership :   
Peter A. Thompson : Verbindungen